Global Cardiovascular Disease Market to 2022 - Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth


#869174

192pages

GBI Research

$ 4995

In Stock

Cardiovascular disease (CVD) covers a range of difference diseases and conditions affecting the heart and/or blood vessels. The most crucial risk factors for CVD are hypertension and dyslipidemia of which accelerate the development of atherosclerotic plaques building up within blood vessels. As atheroma develops its causes stenosis of the blood vessels which can restrict blood flow to the body, brain or heart depending on its locale. It is also possible for the fibrous cap of the plaque to break off, triggering the coagulation cascade and causing a thrombus to form locally which can completely occlude blood flow.

The treatments of CVD typically focus on prevention by controlling the risk factors of CVD. As such, the treatments usually fall within three categories: Anti-hypertensives aim to lower blood pressure; anti-dyslipidemia drugs aim to alter lipid levels to an acceptable range; and anti-thrombotic drugs aim to either prevent thrombus forming or work to mitigate the damage of a current thrombi, they do this by either interrupting the coagulation cascade or inhibiting platelet aggregation, both of which inhibit blood from clotting.

There has been vast scientific innovation within the CVD therapeutics market over recent decades, particularly within the anti-dyslipidemia market with the advent of statins such as Lipitor, the best-selling drug of all time, which produce marked reductions in cholesterol levels. More recently, the commonly used direct factor Xa inhibitors which produce anti-coagulant effects, have been made available for oral administration and the advent of PCSK9 inhibitors provide a viable alternative dyslipidemia treatment for when statins are unsuitable or inefficient. There are currently 1368 pipeline drugs within the cardiovascular disease market, the largest therapy area being thrombosis, with 406 pipeline products indicated for treatment or prevention of thrombotic events.

Among those pipeline drugs expected for imminent release to market there is a mixture of first-in-class products, typically anti-dyslipidemia drugs aiming to provide alternatives to statin therapy, and drugs belonging to currently popular classes such as the aforementioned PCSK9 inhibitors and direct factor Xa inhibitors.

Scope

  • Analysis of innovation in the CVD market in the context of the overall pipeline and current market landscape. Also includes analysis of the deals landscape, including both licensing deals and co-development deals. Key indications covered in detail include hypertension, dyslipidemia and thrombotic events.
  • A brief introduction to CVD, including symptoms, pathophysiology, and an overview of pharmacotherapy for the key diseases.
  • Identification of key marketed products, with a focus on historical and forecast sales patterns and an overview of each drug’s mechanism of action.
  • Comprehensive review of the pipeline, analyzed on the basis of stage of development, molecule type and molecular target.
  • In-depth market forecasting from 2015 to 2022. The forecasts will provide an understanding of how epidemiology trends, new drug entries and drug patent expirations will influence market value.
  • Identification and assessment of key pipeline products, with a particular focus on those due to be brought to market in the near future, as well as a sales forecast for these products.
  • Identification of the leading companies in the market, in terms of market share and growth. Company analysis determines how dependent these companies are on CVD product revenue. In addition, analysis determines the primary factors that will drive market growth for the key companies.
  • Assessment of the licensing and co-development deal landscape for CVD therapies.

Reasons to buy

This report will allow you to 

  • Understand the current clinical and commercial landscape through a comprehensive analysis of the innovation in the CVD market in the context of the overall pipeline and current market landscape. Also includes analysis of the deals landscape, including both licensing deals and co-development deals. Key indications covered in detail include hypertension, dyslipidemia and thrombotic events
  • Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns and an overview of the drug’s mechanism of action.
  • Analyze the CVD pipeline through a comprehensive review of the pipeline, segmented by stage of development, molecule type and molecular target. This review also provides a detailed look at CVD clinical trials as to provide an insight into the risk associated with attempting to bring CVD pipeline drugs.
  • Predict growth in market size, with in-depth market forecasting from 2015 to 2022. The forecast will provide an understanding of how epidemiology trends, new drug entries and new drug patents expirations will influence market value.
  • Identify the key pipeline products, with a particular focus on those due to be brought to market in the near future, as well as a sales forecast for these products.
  • Identify the leading companies in the market, in terms of market share and growth. Company analysis determines how dependent the key companies in the market are on revenue derived from CVD products. In addition, analysis determines the primary factors that will drive market growth for the key companies in the market.
  • Identify commercial opportunities in the CVD deals landscape by analyzing trends in licensing and co-development deals.

Table of Contents

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8

2 Introduction 11
2.1 Therapy Area Introduction 11
2.2 Symptoms 11
2.3 Etiology, Pathophysiology, Comorbidities and Complications 12
2.3.1 Hypertension 12
2.3.2 Dyslipidemia 13
2.3.3 Thrombotic events 15
2.4 Diagnosis 17
2.4.1 Hypertension 17
2.4.2 Dyslipidemia 17
2.4.3 Thrombotic events 18
2.5 Prognosis 18
2.6 Epidemiology Patterns and Forecasts - Prevalence and Patient Segmentation 19
2.6.1 Hypertension 20
2.6.2 Dyslipidemia 21
2.6.3 Thrombotic events 21
2.7 Treatment 22
2.7.1 Thiazide Diuretics 23
2.7.2 Angiotensin Converting Enzyme Inhibitors 24
2.7.3 Angiotensin Receptor Blockers 25
2.7.4 Calcium Channel Blockers 25
2.7.5 Statins 25
2.7.6 Anticoagulants 26
2.7.7 Antiplatelet Drugs 27
2.7.8 Beta-adrenoceptor antagonists (Beta blockers) 27
2.7.9 Other Drugs 28

3 Key Marketed Products 29
3.1 Overview 29
3.2 Crestor (rosuvastatin) - AstraZeneca 29
3.3 Zetia (ezetimibe) - Merck & Co 30
3.4 Lipitor (atorvastatin) - Pfizer 32
3.5 Praluent (alirocumab) - Sanofi 34
3.6 Xarelto (rivaroxaban) - Bayer 35
3.7 Eliquis (apixaban) - Bristol-Myers Squibb and Pfizer 37
3.8 Plavix (clopidogrel) - Sanofi 38
3.9 Brilinta (ticagrelor) - AstraZeneca 40
3.10 Entresto (valsartan plus sacubitril) - Novartis 41
3.11 Benicar (olmesartan medoxomil) - Daiichi Sankyo 43
3.12 Conclusion 44

4 Pipeline Landscape Assessment 46
4.1 Overview 46
4.2 Pipeline Development Landscape 46
4.3 Molecular Targets in the Pipeline 49
4.4 Clinical Trials 53
4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target 53
4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target 57
4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target 60
4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target 63
4.5 Conclusion 66

5 Multi-Scenario Market Forecast to 2022 67
5.1 Overall Market Size 67
5.2 Generic Penetration 69
5.3 Revenue Forecast by Molecular Target 70
5.3.1 Coagulation Cascade 71
5.3.2 P2Y12 Receptors 71
5.3.3 Beta 1 Adrenergic Receptors 72
5.3.4 PCSK9 Inhibitors 73
5.3.5 HMG-CoA Reductase Inhibitors (statins) 74
5.3.6 Renin angiotensin system (RAS) 75
5.3.7 Revenue and Market Share Analysis by Company 75
5.3.8 Assessment of Key Pipeline Products 86

6 Company Analysis and Positioning 93
6.1 Company Landscape 94
6.2 Marketed and Pipeline Portfolio Analysis 95

7 Strategic Consolidations 99
7.1 Licensing Deals 99
7.1.1 Deals by Region, Year and Value 99
7.1.2 Deals by Stage of Development and Value 101
7.1.3 Deals by Molecule Type, Mechanism of Action and Value 102
7.1.4 Licensing Deals Valued Above $200m 104
7.2 Co-development Deals 106
7.2.1 Deals by Region, Year and Value 106
7.2.2 Deals by Stage of Development and Value 107
7.2.3 Deals by Molecule Type, Mechanism of Action and Value 107
7.2.4 Co-development Deals Valued Above $100m 109

8 Appendix 111
8.1 References 111
8.2 Tables of All Pipeline Products 116
8.3 Table of Epidemiology Forecast 186
8.4 Abbreviations 188
8.5 Methodology 189
8.5.1 Coverage 190
8.5.2 Secondary Research 190
8.5.3 Market Size and Revenue Forecasts 190
8.5.4 Pipeline Analysis 191
8.5.5 Competitive Landscape 191
8.6 Contact Us 191
8.7 Disclaimer 191

Table 1: Cardiovascular Disease Therapeutics Market, Total Cholesterol, LDL and HDL Levels and Corresponding Category 17
Table 2: Cardiovascular Disease Therapeutics Market, Global, Epidemiology of Cardiovascular Disease, 2016 20
Table 3: Cardiovascular Disease Therapeutics Market, Global, Approved Indications for Crestor, 2016 29
Table 4: Cardiovascular Disease Therapeutics Market, Global, Approved Indications for Zetia, 2016 31
Table 5: Cardiovascular Disease Therapeutics Market, Global, Approved Indications for Lipitor, 2016 33
Table 6: Cardiovascular Disease Therapeutics Market, Global, Approved Indications for Praluent, 2016 34
Table 7: Cardiovascular Disease Therapeutics Market, Global, Approved Indications for Xarelto, 2016 36
Table 8: Cardiovascular Disease Therapeutics Market, Global, Approved Indications for Eliquis, 2016 37
Table 9: Cardiovascular Disease Therapeutics Market, Global, Approved Indications for Plavix, 2016 39
Table 10: Cardiovascular Disease Therapeutics Market, Global, Approved Indications for Brilinta, 2016 40
Table 11: Cardiovascular Disease Therapeutics Market, Global, Approved Indications for Entresto, 2016 41
Table 12: Cardiovascular Disease Therapeutics Market, Global, Approved Indications for Benicar, 2016 43
Table 13: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue Forecast for Key Products ($bn), 2015-2022 68
Table 14: Cardiovascular Disease Therapeutics Market, Global, Usage of Generics Across Key Indications, 2015 70
Table 15: Cardiovascular Disease Therapeutics Market, Global, Forecast Revenues by Company, 2015-2022 76
Table 16: Cardiovascular Disease Therapeutics Market, Global, Licensing Deals, 2006-2016 104
Table 17: Cardiovascular Disease Therapeutics Market, Global, Co-development Deals, 2006-2016 109
Table 18: Cardiovascular Disease Therapeutics Market, Global, Pipeline Products, Discovery, 2016 116
Table 19: Cardiovascular Disease Therapeutics Market, Global, Pipeline Products, Preclinical, 2016 126
Table 20: Cardiovascular Disease Therapeutics Market, Global, Pipeline Products, IND/CTA-filed, 2016 165
Table 21: Cardiovascular Disease Therapeutics Market, Global, Pipeline Products, Phase I, 2016 165
Table 22: Cardiovascular Disease Therapeutics Market, Global, Pipeline Products, Phase II, 2016 170
Table 23: Cardiovascular Disease Therapeutics Market, Global, Pipeline Products, Phase III, 2016 178
Table 24: Cardiovascular Disease Therapeutics Market, Global, Pipeline Products, Pre-registration, 2016 184
Table 25: Cardiovascular Disease Therapeutics Market, Global, Pipeline Products, Unknown, 2016 186
Table 26: Cardiovascular Disease Therapeutics Market, Prevalence Patterns for Hypertension, 2015-2022 186
Table 27: Cardiovascular Disease Therapeutics Market, Prevalence Patterns for Dyslipidemia, 2015-2022 187
Table 28: Cardiovascular Disease Therapeutics Market, Prevalence Patterns for Acute Coronary Syndrome, 2015-2022 187
Table 29: Cardiovascular Disease Therapeutics Market, Prevalence Patterns for Ischemic Stroke, 2015-2022 187
Table 30: Cardiovascular Disease Therapeutics Market, Incident Cases for Venous Thromboembolism, 2015-2022 188
Table 31: Abbreviations 188

Figure 1: Cardiovascular Disease Therapeutics Market, Global, Epidemiology Patterns for Hypertension, 2015-2022 20
Figure 2: Cardiovascular Disease Therapeutics Market, Global, Epidemiology Patterns for Dyslipidemia, 2015-2022 21
Figure 3: Cardiovascular Disease Therapeutics Market, Global, Epidemiology Patterns for Acute Coronary Syndrome, Ischemic Stroke and Venous Thromboembolism, 2015-2022 22
Figure 4: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue for Crestor ($bn), 2006-2022 30
Figure 5: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue for Zetia ($bn), 2006-2022 32
Figure 6: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue for Lipitor ($bn), 2006-2022 34
Figure 7: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue for Praluent ($bn), 2006-2022 35
Figure 8: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue for Xarelto ($bn), 2006-2022 37
Figure 9: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue for Eliquis ($bn), 2006-2022 38
Figure 10: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue for Plavix ($bn), 2006-2022 40
Figure 11: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue for Brilinta ($bn), 2006-2022 41
Figure 12: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue for Entresto ($bn), 2006-2022 42
Figure 13: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue for Benicar ($bn), 2006-2022 44
Figure 14: Cardiovascular Disease Therapeutics Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2016 46
Figure 15: Cardiovascular Disease Therapeutics Market, Global, Pipeline for Cardiovascular Diseases by Stage of Development, Molecule Type and Program Type, 2016 47
Figure 16: Cardiovascular Disease Therapeutics Market, Global, Pipeline for Key Cardiovascular Disease Indications by Stage of Development, 2016 48
Figure 17: Cardiovascular Disease Therapeutics Market, Global, Pipeline for Key Cardiovascular Disease Indications by Molecule Type, 2016 49
Figure 18: Cardiovascular Disease Therapeutics Market, Global, Pipeline by Molecular Target, 2016 51
Figure 19: Cardiovascular Disease Therapeutics Market, Global, Pipeline by Molecular Target and Stage of Development, 2016 52
Figure 20: Cardiovascular Disease Therapeutics Market, Global, Pipeline for Key Cardiovascular Disease Indications by Molecular Target, 2016 53
Figure 21: Cardiovascular Disease Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006-2016 54
Figure 22: Cardiovascular Disease Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006-2016 55
Figure 23: Cardiovascular Disease Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2016 56
Figure 24: Cardiovascular Disease Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2016 57
Figure 25: Cardiovascular Disease Therapeutics Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2016 57
Figure 26: Cardiovascular Disease Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2016 58
Figure 27: Cardiovascular Disease Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2016 59
Figure 28: Cardiovascular Disease Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2016 60
Figure 29: Cardiovascular Disease Therapeutics Market, Global, Clinical Trial Size by Stage of Development (participants), 2006-2016 60
Figure 30: Cardiovascular Disease Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006-2016 61
Figure 31: Cardiovascular Disease Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2016 62
Figure 32: Cardiovascular Disease Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006-2016 63
Figure 33: Cardiovascular Disease Therapeutics Market, Global, Clinical Program Size by Stage of Development (participants), 2006-2016 64
Figure 34: Cardiovascular Disease Therapeutics Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006-2016 64
Figure 35: Cardiovascular Disease Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006-2016 65
Figure 36: Cardiovascular Disease Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006-2016 66
Figure 37: Cardiovascular Disease Therapeutics Market, Global, Market Size ($bn), 2015-2022 67
Figure 38: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue by Premium and Generic Products ($bn), 2015-2022 69
Figure 39: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue Forecast for Drugs Targeting Elements of the Coagulation Cascade ($bn), 2015-2022 71
Figure 40: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue Forecast for P2Y12 Inhibitors ($bn), 2015-2022 72
Figure 41: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue Forecast for Beta Blockers ($bn), 2015-2022 73
Figure 42: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue Forecast for PCSK9 Inhibitors ($m), 2015-2022 74
Figure 43: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue Forecast for HMG-CoA Inhibitors ($bn), 2015-2022 74
Figure 44: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue Forecast for Drugs Acting on RAS ($bn), 2015-2022 75
Figure 45: Cardiovascular Disease Therapeutics Market, Global, Forecast Market Share by Company (%), 2015-2022 78
Figure 46: Cardiovascular Disease Therapeutics Market, Global, Companies by Compound Annual Growth Rate (%), 2015-2022 79
Figure 47: Cardiovascular Disease Therapeutics Market, Global, Revenues by Product Type, 2015-2022 80
Figure 48: Cardiovascular Disease Therapeutics Market, Global, Sanofi Annual Revenue Forecast ($bn), 2015-2022 81
Figure 49: Cardiovascular Disease Therapeutics Market, Global, AstraZeneca Annual Revenue Forecast ($bn), 2015-2022 82
Figure 50: Cardiovascular Disease Therapeutics Market, Global, Novartis Annual Revenue Forecast ($bn), 2015-2022 83
Figure 51: Cardiovascular Disease Therapeutics Market, Global, Bayer Annual Revenue Forecast ($bn), 2015-2022 84
Figure 52: Cardiovascular Disease Therapeutics Market, Global, Pfizer Annual Revenue Forecast ($bn), 2015-2022 85
Figure 53: Cardiovascular Disease Therapeutics Market, Global, Merck Annual Revenue Forecast ($bn), 2015-2022 86
Figure 54: Cardiovascular Disease Therapeutics Market, Global, Revenue Forecast for Bococizumab ($m), 2018-2022 87
Figure 55: Cardiovascular Disease Therapeutics Market, Global, Revenue Forecast for Betrixaban ($m), 2017-2022 88
Figure 56: Cardiovascular Disease Therapeutics Market, Global, Revenue Forecast for Anacetrapib ($m), 2018-2022 89
Figure 57: Cardiovascular Disease Therapeutics Market, Global, Revenue Forecast for Volanesorsen ($m), 2017-2022 90
Figure 58: Cardiovascular Disease Therapeutics Market, Global, Revenue Forecast for Vericiguat ($m), 2018-2022 91
Figure 59: Cardiovascular Disease Therapeutics Market, Global, Revenue Forecast for ETC-1002 ($m), 2018-2022 92
Figure 60: Cardiovascular Disease Therapeutics Market, Global, Cluster by Growth and Market Share, 2015-2022 93
Figure 61: Cardiovascular Disease Therapeutics Market, Global, Companies by Type, 2016 95
Figure 62: Cardiovascular Disease Therapeutics Market, Global, Pipeline, High-Activity and Late-Stage Developers by Level of Cardiovascular Specialization, 2016 96
Figure 63: Cardiovascular Disease Therapeutics Market, Global, Proportion of Total Company Revenue Attributed to Cardiovascular Disease, 2015-2022 97
Figure 64: Cardiovascular Disease Therapeutics Market, Global, Top Six Companies, Proportion of Total Company Revenue Attributed to Cardiovascular Disease ($bn), 2015-2022 98
Figure 65: Cardiovascular Disease Therapeutics Market, Global, Licensing Deals, 2006-2016 100
Figure 66: Cardiovascular Disease Therapeutics Market, Global, Licensing Deals by Indication, 2006-2016 101
Figure 67: Cardiovascular Disease Therapeutics Market, Global, Licensing Deals by Stage of Development and Value, 2006-2016 102
Figure 68: Cardiovascular Disease Therapeutics Market, Global, Licensing Deals by Molecule Type and Mechanism of Action, 2006-2016 103
Figure 69: Cardiovascular Disease Therapeutics Market, Global, Co-development Deals, 2006-2016 106
Figure 70: Cardiovascular Disease Therapeutics Market, Global, Co-development Deals by Indication, 2006-2016 107
Figure 71: Cardiovascular Disease Therapeutics Market, Global, Co-development Deals by Molecule Type and Mechanism of Action, 2006-2016 108